Trial reportJournal of the National Cancer Institute1998
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
Trial report in Journal of the National Cancer Institute, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00091611 (Phase II Study in Metastatic Renal Cell Cancer Using Cultured, Tumor-Reactive Lymphocytes and Interleukin-2), which is not on this map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study in Metastatic Renal Cell Cancer Using Cultured, Tumor-Reactive Lymphocytes and Interleukin-2
Who cites it
83 citing papers in PubMed, 305 citations in OpenAlex.
- Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.Cancer immunology, immunotherapy : CII · 2005Trial
- Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2003Trial
- Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.Human gene therapy · 2003Trial
- Review
- Four decades of adenovirus gene transfer vectors: History and current use.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.Pharmaceutics · 2025Review
- The Evolving T Cell Receptor Recognition Code: The Rules Are More Like Guidelines.Immunological reviews · 2025Review
- Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.Cancers · 2024Review
- Article
- Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.EMBO molecular medicine · 2021Article
- Metabolism and immunity in breast cancer.Frontiers of medicine · 2021Review
- Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.Cell host & microbe · 2021Article
- Autophagy in Parkinson's Disease.Journal of molecular biology · 2020Review
- Engineering patient-specific cancer immunotherapies.Nature biomedical engineering · 2019Review
- ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis.Cancer immunology research · 2018Article
- The Journey ofFrontiers in immunology · 2018Review
- From kinetics and cellular cooperations to cancer immunotherapies.Oncotarget · 2016Review
- Melanoma immunotherapy.Cancer biology & therapy · 2014Review
- Trial Watch: Peptide vaccines in cancer therapy.Oncoimmunology · 2013Review
- Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application.Cancer gene therapy · 2013Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe characterization of the genes encoding melanoma-associated antigens MART-1 or gp100, recognized by T cells, has opened new possibilities for the development of immunization strategies for patients with metastatic melanoma. With the use of recombinant adenoviruses expressing either MART-1 or gp100 to immunize patients with metastatic melanoma, we evaluated the safety, immunologic, and potential therapeutic aspects of these immunizations.
methodsIn phase I studies, 54 patients received escalating doses (between 10(7) and 10(11) plaque-forming units) of recombinant adenovirus encoding either MART-1 or gp100 melanoma antigen administered either alone or followed by the administration of interleukin 2 (IL-2). The immunologic impact of these immunizations on the development of cellular and antibody reactivity was assayed.
resultsRecombinant adenoviruses expressing MART-1 or gp100 were safely administered. One of 16 patients with metastatic melanoma receiving the recombinant adenovirus MART-1 alone experienced a complete response. Other patients achieved objective responses, but they had received IL-2 along with an adenovirus, and their responses could be attributed to the cytokine. Immunologic assays showed no consistent immunization to the MART-1 or gp100 transgenes expressed by the recombinant adenoviruses. High levels of neutralizing antibody were found in the pretreatment sera of the patients.
conclusionsHigh doses of recombinant adenoviruses could be safely administered to cancer patients. High levels of neutralizing antibody present in patients' sera prior to treatment may have impaired the ability of these viruses to immunize patients against melanoma antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.